Theriva Biologics, Inc.
TOVXTheriva Biologics, Inc. in brief
Theriva Biologics, Inc. is a listed company in the Biotechnology industry, based in Rockville, Maryland, USA. Its market value was $10 M on 13 October 2026, which makes it the 25,846th largest listed company in the world and the 4,298th largest in the USA on this site. It employs about 15 people. Its shares trade under the symbol TOVX (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Theriva Biologics, Inc.
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L., in March 2022, as described in more detail below, we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer, and a Phase 1 clinical study for the treatment of retinoblastoma, as well as various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma.
From the company's annual report filed with the US SEC: read the report
Theriva Biologics, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1997
- ✎Renamed Sheffield Pharmaceuticals IncFormerly Sheffield Medical Technologies Inc.
- 2006
- ✎Renamed Pipex Pharmaceuticals, Inc.Formerly Sheffield Pharmaceuticals Inc.
- 2008
- ✎Renamed Adeona Pharmaceuticals, Inc.Formerly Pipex Pharmaceuticals, Inc..
- 2012
- ✎Renamed Synthetic Biologics, Inc.Formerly Adeona Pharmaceuticals, Inc..
- 2022
- ✎Renamed Theriva Biologics, Inc.Formerly Synthetic Biologics, Inc..
Events of Theriva Biologics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,674 (Dec 2022) · #5,421 (Jul 2023) · #4,557 (Jan 2024) · #2,400 (Mar 2026) · #4,048 (Aug 2026) · #4,247 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.7×
- Free cash flow yield
- -165.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -154.4%
- Liabilities / assets
- 59.8%
- Net debt
- $-11M
- R&D / revenue
- 60.5%
- Profit per employee
- $-1.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-24M | $-24M | — |
| Dec 2024 | — | — | $-26M | $-26M | — |
| Dec 2023 | — | — | $-21M | $-18M | — |
| Dec 2022 | — | — | $-22M | $-20M | — |
| Dec 2021 | — | — | $-14M | $-14M | — |
| Dec 2020 | — | — | $-10M | $-10M | — |
| Dec 2019 | — | — | $-16M | $-15M | — |
| Dec 2018 | — | — | $-18M | $-13M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-17M | $0M | $-17M | $-2.08 | — |
| Dec 2024 | $-17M | $0M | $-17M | $-19.03 | — |
| Dec 2023 | $-19M | $0M | $-19M | $-28.48 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-1.31 | — |
| Dec 2021 | $-13M | $0M | $-13M | $-1.90 | — |
| Dec 2020 | $-12M | $0M | $-12M | $-0.66 | — |
| Dec 2019 | $-14M | $0M | $-14M | $-0.98 | — |
| Dec 2018 | $-17M | $0M | $-17M | $-4.06 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 2, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Regulation FD disclosure
- Oct 20, 2026DEF 14AProxy statement
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Aug 6, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 4, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jul 7, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 29, 2026DEF 14AProxy statement
- Jun 11, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 5, 20268-KCurrent reportOther events
Official filings of Theriva Biologics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-24 M
- Net income
- $-24 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $38 M
- Total liabilities
- $23 M
- Total equity
- $15 M
As of December-2025
Top 26 institutional investors in Theriva Biologics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 486,179 | 0 (0.00%) | 1.06% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 299,138 | +5,117 (+1.74%) | 0.65% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 241,780 | 0 (0.00%) | 0.53% | $0 M | Nov 13, 2026 |
| 4 | Jane Street Group, LLC | 161,106 | -170,816 (-51.46%) | 0.35% | $0 M | Nov 12, 2026 |
| 5 | Ikarian Capital, LLC | 112,076 | 0 (0.00%) | 0.24% | $0 M | Nov 16, 2026 |
| 6 | Renaissance Technologies LLC | 109,500 | +45,790 (+71.87%) | 0.24% | $0 M | Nov 12, 2026 |
| 7 | XTX Topco Ltd | 102,846 | +48,978 (+90.92%) | 0.22% | $0 M | Nov 16, 2026 |
| 8 | Northern Trust Corp | 82,700 | 0 (0.00%) | 0.18% | $0 M | Nov 16, 2026 |
| 9 | Two Sigma Securities, LLC | 55,904 | +36,156 (+183.09%) | 0.12% | $0 M | Nov 16, 2026 |
| 10 | StoneX Group Inc. | 32,106 | New | 0.07% | $0 M | Nov 3, 2026 |
| 11 | Boothbay Fund Management, LLC | 27,646 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 12 | Morgan Stanley | 20,299 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 13 | Ground Swell Capital, LLC | 18,410 | -16,882 (-47.84%) | 0.04% | $0 M | Nov 9, 2026 |
| 14 | Two Sigma Investments, LP | 15,437 | -19 (-0.12%) | 0.03% | $0 M | Nov 16, 2026 |
| 15 | Schwarz Dygos Wheeler Investment Advisors LLC | 15,000 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 16 | UBS Group AG | 13,983 | -47,070 (-77.10%) | 0.03% | $0 M | Nov 10, 2026 |
| 17 | BlackRock, Inc. | 7,504 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 18 | SBI Securities Co., Ltd. | 1,083 | +725 (+202.51%) | 0.00% | $0 M | Oct 22, 2026 |
| 19 | Osaic Holdings, Inc. | 440 | -1 (-0.23%) | 0.00% | $0 M | Nov 12, 2026 |
| 20 | Strategic Financial Concepts, LLC | 163 | New | 0.00% | $0 M | Nov 16, 2026 |
| 21 | IFP Advisors, Inc | 11 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 22 | Tower Research Capital LLC (TRC) | 5 | New | 0.00% | $0 M | Nov 16, 2026 |
| 23 | NFSG Corp | 5 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 24 | Barclays PLC | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 25 | Wells Fargo & Company/mn | 2 | New | 0.00% | $0 M | Nov 16, 2026 |
Show all 26: investors 26 to 26
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Theriva Biologics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 486,179 | $0 M | 1.1% | <0.01% | +153% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 284,723 | $0 M | 0.62% | <0.01% | +48% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 26,070 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 31 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Theriva Biologics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +14,000 | $0.690 | $10 K | 250,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +26,000 | $0.630 | $16 K | 236,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +25,000 | $1.040 | $26 K | 210,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +25,000 | $0.940 | $24 K | 185,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +25,000 | $0.870 | $22 K | 160,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +25,000 | $0.750 | $19 K | 135,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +100,000 | $0.440 | $44 K | 110,000 | Form 4 |
| filed | Steven A. ShallcrossCEO and CFO, Director | Buy | +50,000 | $0.490 | $25 K | 100,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Theriva Biologics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 10-for-1 split
Bankruptcy filing: (8-K)
Fails to deliver
- : 93,707 shares at $0.22
- : 26,663 shares at $0.23
- : 7,920 shares at $0.23
- : 3,982 shares at $0.23
- : 3,050 shares at $0.23
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Theriva Biologics, Inc. scorecard#
Passes 4 of the 14 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-165.4%Free cash flow is -165.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.08 vs -19.03Diluted EPS -2.08 in fiscal 2025 against -19.03 the year before (report's currency).
- ✗Net income higher than five years earlier-$24 M-$24 M in fiscal 2025 against -$10 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-137.8%-137.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.75 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $11 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-400.8×Operating income -400.8 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Theriva Biologics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 8.6−28.5%— | 12−15.9%— | 14+22.1%— | 12+50.3%— | 7.8+52.0%— | 5.1−53.7%— | 11−6.4%— | 12−36.9%— | 19−35.5%— | 29—— | |
| General and administrative | 15+109%— | 7.4+3.9%— | 7.1−27.8%— | 9.9+52.3%— | 6.5+28.7%— | 5.0+9.8%— | 4.6−20.0%— | 5.7−23.3%— | 7.5−26.4%— | 10—— | |
| Operating expenses | 24−8.7%— | 26+22.9%— | 21−0.7%— | 22+51.2%— | 14+40.5%— | 10−35.1%— | 16−10.9%— | 18−33.1%— | 26−33.1%— | 39—— | |
| Operating income | −24—— | −26—— | −21—— | −22—— | −14—— | −10—— | −16—— | −18—— | −26—— | −39—— | |
| Interest and finance income | 0.3−58.8%— | 0.7−51.6%— | 1.4+181%— | 0.5+8433%— | 0.0−86.4%— | 0.0−84.5%— | 0.3+322%— | 0.1+219%— | 0.0−43.2%— | 0.0—— | |
| Interest expense and finance costs | 0.1+917%— | 0.0—— | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.3−55.0%— | 0.7−51.9%— | 1.4+206%— | 0.5+7750%— | 0.0−86.4%— | 0.0−84.5%— | 0.3−93.2%— | 4.2−61.4%— | 11−6.0%— | 11—— | |
| Income before tax | −24—— | −26—— | −20—— | −21—— | −14—— | — | — | — | — | — | |
| Income tax | — | 0—— | −1.6—— | −1.4—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −24—— | −26—— | −18—— | −20—— | −14—— | −10—— | −15—— | −13—— | −15—— | −28—— | |
| Minority interests' share of net income | — | — | — | 0—— | −0.0—— | −0.1—— | −0.1—— | −0.1—— | −0.3—— | −0.5—— | |
| Net income attributable to shareholders | — | — | −18—— | −20—— | −14—— | −10—— | −15—— | −13—— | −15—— | −27—— | |
| Earnings per share, basic | -2.08—— | -19.03—— | -28.48r-1.14—— | -1.31—— | -1.90r-0.19—— | -0.66—— | -0.98—— | -4.06—— | -6.23r-0.18—— | -0.29—— | |
| Earnings per share, diluted | -2.08—— | -19.03—— | -28.48r-1.14—— | -1.31—— | -1.90r-0.19—— | -0.66—— | -0.98—— | -4.06—— | -6.23r-0.18—— | -0.29—— | |
| Shares, weighted average (basic) | 12+801%— | 1.3+109%— | 0.6r16−95.8%— | 15+25.8%— | 12r122−35.9%— | 19—— | — | — | — | — | |
| Shares, weighted average (diluted) | 12+801%— | 1.3+109%— | 0.6r16−95.8%— | 15+25.8%— | 12r122−35.9%— | 19+15.7%— | 16+164%— | 6.2+75.4%— | 3.6r124−96.2%— | 94—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 13+12.5%34.1% | 12−49.9%32.8% | 23−44.5%42.0% | 42−37.9%58.1% | 67+981%95.7% | 6.2−58.6%74.0% | 15−48.0%87.3% | 29+69.0%95.9% | 17−10.2%90.9% | 19—84.7% | |
| Other current assets | 1.1−26.6%2.8% | 1.4−40.2%4.1% | 2.4−35.4%4.4% | 3.7+144%5.2% | 1.5−10.2%2.2% | 1.7+23.6%20.3% | 1.4+133%8.0% | 0.6−28.3%2.0% | 0.8+347%4.4% | 0.2—0.8% | |
| Current assets | 17+7.3%45.7% | 16−40.6%46.1% | 27−39.8%49.6% | 46−33.9%63.3% | 69+768%97.9% | 7.9−51.7%94.3% | 16−44.3%95.3% | 30+64.5%97.9% | 18−16.8%95.2% | 22—95.9% | |
| Property, plant and equipment | 0.2−17.8%0.6% | 0.3−36.0%0.8% | 0.4+22.3%0.8% | 0.3+242%0.5% | 0.1−42.0%0.1% | 0.2−52.6%2.1% | 0.4−39.5%2.1% | 0.6−30.4%2.0% | 0.9−3.6%4.6% | 0.9—4.0% | |
| Right-of-use (leased) assets | 0.8−36.9%2.1% | 1.3−27.7%3.6% | 1.8+46.7%3.2% | 1.2−13.3%1.7% | 1.4+396%2.0% | 0.3−33.4%3.3% | 0.4—2.4% | 0—0.0% | — | — | |
| Goodwill | — | 0−100%0.0% | 5.7+3.2%10.3% | 5.5—7.7% | 0—0.0% | — | — | — | — | — | |
| Other intangible assets | 20+13.0%51.3% | 17−12.1%49.1% | 20+3.2%35.8% | 19—26.6% | — | — | — | — | — | — | |
| Total assets | 38+8.2%100% | 35−36.0%100% | 55−23.2%100% | 72+2.1%100% | 70+737%100% | 8.4−51.2%100% | 17−42.8%100% | 30+60.0%100% | 19−16.3%100% | 22—100% | |
| Accounts payable | 1.0+18.0%2.7% | 0.9+11.6%2.4% | 0.8−15.8%1.4% | 0.9+74.6%1.3% | 0.5−40.9%0.7% | 0.9−61.7%10.5% | 2.3+124%13.4% | 1.0−48.8%3.4% | 2.0+1.4%10.7% | 2.0—8.9% | |
| Current liabilities | 10+32.0%26.2% | 7.6+12.6%21.5% | 6.7−4.6%12.2% | 7.1+98.6%9.8% | 3.6+19.8%5.1% | 3.0−43.8%35.3% | 5.3+55.9%30.6% | 3.4−65.4%11.2% | 9.8−50.4%52.0% | 20—87.8% | |
| Lease liabilities (non-current) | 0.4−59.7%0.9% | 0.9−39.5%2.5% | 1.4+21.5%2.6% | 1.2−15.4%1.7% | 1.4+654%2.0% | 0.2−60.7%2.2% | 0.5—2.7% | 0—0.0% | — | — | |
| Total liabilities | 23+40.4%59.8% | 16+4.9%46.1% | 16−10.3%28.1% | 17+249%24.1% | 5.0+57.3%7.0% | 3.2−45.2%37.5% | 5.7+55.9%33.4% | 3.7−63.8%12.2% | 10−49.7%54.1% | 20—90.0% | |
| Retained earnings | −359—−938% | −335—−948% | −309—−560% | −291—−405% | −271—−386% | −248—−2950% | −236—−1367% | −219—−728% | −194—−1031% | −172—−765% | |
| Shareholders' equity | — | — | — | — | 65—93.0% | −4.8−362%−56.7% | 1.8−89.3%10.6% | 17—56.6% | −1.5−139%−7.9% | 3.8—17.1% | |
| Minority interests | — | — | — | — | — | −2.8—−33.0% | −2.9—−16.7% | −2.9—−9.7% | −1.9—−10.2% | −1.6—−7.1% | |
| Total equity | 15−19.3%40.2% | 19−48.4%53.9% | 37−28.7%66.9% | 52−20.8%72.1% | 65—93.0% | −7.5—−89.7% | −1.1−107%−6.1% | 14r14—47.0% | −3.4−251%−18.1% | 2.3r2.2—10.0% | |
| Total liabilities and equity | 38+8.2%100% | 35−36.0%100% | 55−23.2%100% | 72+2.1%100% | 70+737%100% | 8.4−51.2%100% | 17−42.8%100% | 30+60.0%100% | 19−16.3%100% | 22—100% | |
| Shares outstanding | 36+1183%— | 2.8+305%— | 0.7r17−95.5%— | 15r15+14.5%— | 13r132−54.9%— | 29+74.0%— | 17+8.6%— | 15+322%— | 3.7r129−96.9%— | 117—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1−21.2%— | 0.1+1.5%— | 0.1+58.8%— | 0.1−2.3%— | 0.1−56.7%— | 0.2−16.2%— | 0.2−11.8%— | 0.3+11.0%— | 0.2+56.1%— | 0.2—— | |
| Share-based compensation | 0.7−2.5%— | 0.7+21.6%— | 0.6+16.2%— | 0.5+14.2%— | 0.4+18.9%— | 0.4+2.9%— | 0.3−83.6%— | 2.1−39.2%— | 3.4−15.0%— | 4.0—— | |
| Cash from operating activities | −17—— | −17—— | −19—— | −19—— | −13—— | −12—— | −14—— | −17—— | −20—— | −28—— | |
| Capital expenditure | −0.0—— | −0.0—— | −0.2—— | −0.1—— | −0.0—— | −0.0—— | 0—— | −0.0—— | −0.2—— | −0.6—— | |
| Cash from investing activities | −0.0—— | −0.0—— | −0.2—— | −4.4—— | −0.0—— | −0.0—— | 0—— | −0.0—— | −0.2—— | −0.6—— | |
| Debt issued | 1.5—— | — | — | — | — | — | — | — | — | — | |
| Debt repaid | — | −0.1—— | −0.1—— | −1.4—— | 0—— | — | — | — | — | — | |
| Shares issued | — | — | — | 0−100%— | 66+1864%— | 3.4—— | — | 12—— | 0−100%— | 25—— | |
| Cash from financing activities | 18+231%— | 5.5+779%— | 0.6—— | −1.9−103%— | 74+2103%— | 3.4—— | 0−100%— | 29+57.4%— | 18−30.8%— | 27—— | |
| Exchange-rate effect on cash | −0.1—— | −0.1—— | −0.0—— | −0.0—— | 0—— | — | — | — | — | — | |
| Change in cash | 1.4—— | −12—— | −19—— | −25−142%— | 61—— | — | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0*—— | 0*—— | 0.3—100% | — | — | — | — | — | — | — | — | — | |
| Research and development | 3.4−67.5%— | 0.6−76.0%— | 1.3−35.1%— | 0.4−88.0%118% | 1.1*−60.8%— | 2.6−6.7%— | 2.0−33.9%— | 3.0−14.2%— | 2.9*−31.2%— | 2.7—— | 3.0—— | 3.5—— | 4.2*—— | |
| General and administrative | 6.0−63.3%— | 0.9−51.1%— | 2.0−81.9%— | 2.1+43.0%691% | 0.9*−45.0%— | 1.9−17.9%— | 11+662%— | 1.4−25.0%— | 1.7*−16.2%— | 2.3—— | 1.5—— | 1.9—— | 2.0*—— | |
| Operating expenses | 9.3−64.9%— | 1.5−65.4%— | 3.3−74.9%— | 2.4−45.1%809% | 2.1*−55.0%— | 4.4−43.7%— | 13+54.7%— | 4.4−18.1%— | 4.6*−26.3%— | 7.9—— | 8.5—— | 5.4—— | 6.2*—— | |
| Operating income | −9.0—— | −1.5—— | −3.3—— | −2.1—−709% | −2.1*—— | −4.4—— | −13—— | −4.4—— | −4.6*—— | −7.9—— | −8.5—— | −5.4—— | −6.2*—— | |
| Interest and finance income | 0.3−15.9%— | 0.1−1.5%— | 0.1+46.3%— | 0.1−14.6%27.3% | 0.1*−47.8%— | 0.1−58.9%— | 0.1−68.8%— | 0.1−57.9%— | 0.1*−55.8%— | 0.2—— | 0.2—— | 0.2—— | 0.3*—— | |
| Interest expense and finance costs | 0.1—— | 0.00.0%— | 0.0+6.3%— | 0.0+33.3%5.3% | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | — | — | — | — | — | |
| Other non-operating income (expense) | 0.3−23.0%— | 0.1−19.0%— | 0.1+5.4%— | 0.1−10.8%27.7% | 0.1*−49.6%— | 0.1−50.9%— | 0.1−57.0%— | 0.1−59.0%— | 0.1*−56.8%— | 0.2—— | 0.2—— | 0.2—— | 0.3*—— | |
| Income before tax | −8.7—— | −1.5—— | −3.2—— | −2.0—−681% | −2.0*—— | −4.4—— | −13—— | −4.3—— | −4.4*—— | −7.7—— | −8.3—— | −5.2—— | −5.9*—— | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | −0.4*—— | |
| Net income including minority interests | −8.7—— | −1.5—— | −3.2—— | −2.0—−681% | −2.0*—— | −4.4—— | −13—— | −4.3—— | −4.4*—— | −7.7—— | −8.3—— | −5.2—— | −5.5*—— | |
| Net income attributable to shareholders | — | — | — | — | — | — | — | — | — | — | — | — | −5.5*—— | |
| Earnings per share, basic | — | -0.03—— | -0.07—— | -0.05—— | — | -0.45—— | -1.93—— | -1.55—— | — | -6.81—— | -10.72r-0.43—— | -7.53r-0.30—— | — | |
| Earnings per share, diluted | — | -0.03—— | -0.07—— | -0.05—— | — | -0.45—— | -1.93—— | -1.55—— | — | -6.81—— | -10.72r-0.43—— | -7.53r-0.30—— | — | |
| Shares, weighted average (basic) | 46+374%— | 46+374%— | 46+580%— | 41+1376%— | — | 9.7+753%— | 6.8+771%— | 2.8+306%— | — | 1.1—— | 0.8r19—— | 0.7r17—— | — | |
| Shares, weighted average (diluted) | 46+374%— | 46+374%— | 46+580%— | 41+1376%— | — | 9.7+753%— | 6.8+771%— | 2.8+306%— | — | 1.1—— | 0.8r19—— | 0.7r17—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.5—26.8% | 8.5+12.6%26.8% | 11−6.5%32.5% | 14+44.1%37.7% | 13+12.5%34.1% | 7.5−54.1%24.4% | 12−27.0%33.8% | 10−45.2%31.1% | 12−49.9%32.8% | 16—40.9% | 17—39.1% | 18—37.5% | 23—42.0% | |
| Other current assets | 0.5—1.5% | 0.5−27.4%1.5% | 0.7−27.5%1.9% | 0.6−28.0%1.6% | 1.1−26.6%2.8% | 0.7−49.4%2.1% | 0.9−33.9%2.5% | 0.9−46.1%2.7% | 1.4−40.2%4.1% | 1.3—3.2% | 1.4—3.2% | 1.6—3.3% | 2.4—4.4% | |
| Current assets | 11—33.7% | 11+7.3%33.7% | 14−7.3%39.2% | 17+34.3%43.8% | 17+7.3%45.7% | 9.9−49.3%32.1% | 15−25.2%41.1% | 12−42.4%38.8% | 16−40.6%46.1% | 20—48.7% | 20—46.5% | 22—44.4% | 27—49.6% | |
| Property, plant and equipment | 0.2—0.5% | 0.2−37.8%0.5% | 0.2−32.9%0.5% | 0.2−23.3%0.5% | 0.2−17.8%0.6% | 0.2−20.7%0.8% | 0.3−23.2%0.7% | 0.3−32.5%0.8% | 0.3−36.0%0.8% | 0.3—0.8% | 0.3—0.8% | 0.4—0.8% | 0.4—0.8% | |
| Right-of-use (leased) assets | 1.7—5.4% | 1.7+80.9%5.4% | 1.8+69.5%5.2% | 1.9+66.2%5.1% | 0.8−36.9%2.1% | 0.9−34.0%3.1% | 1.1−29.1%3.0% | 1.2−28.3%3.6% | 1.3−27.7%3.6% | 1.4—3.6% | 1.5—3.6% | 1.6—3.4% | 1.8—3.2% | |
| Goodwill | — | — | — | — | — | — | — | — | 0−100%0.0% | — | 1.5—3.5% | 5.6—11.4% | 5.7—10.3% | |
| Other intangible assets | 19—60.1% | 19−3.4%60.1% | 19−2.9%54.7% | 19+6.3%50.3% | 20+13.0%51.3% | 20+5.2%63.6% | 20+2.3%54.8% | 18−6.4%56.2% | 17−12.1%49.1% | 19—46.5% | 19—45.2% | 19—39.6% | 20—35.8% | |
| Total assets | 32—100% | 32+2.3%100% | 35−2.7%100% | 38+18.9%100% | 38+8.2%100% | 31−23.1%100% | 36−15.5%100% | 32−34.0%100% | 35−36.0%100% | 40—100% | 42—100% | 49—100% | 55—100% | |
| Accounts payable | 0.5—1.5% | 0.5−41.3%1.5% | 1.0+62.1%2.8% | 0.6+39.1%1.6% | 1.0+18.0%2.7% | 0.8+5.2%2.6% | 0.6−35.1%1.7% | 0.4−23.5%1.4% | 0.9+11.6%2.4% | 0.8—1.9% | 0.9—2.2% | 0.6—1.2% | 0.8—1.4% | |
| Current liabilities | 8.8—27.8% | 8.8−20.2%27.8% | 12−2.3%34.7% | 10+26.0%26.8% | 10+32.0%26.2% | 11+50.3%35.7% | 12+81.0%34.6% | 8.1+35.6%25.3% | 7.6+12.6%21.5% | 7.3—18.3% | 6.8—16.2% | 6.0—12.3% | 6.7—12.2% | |
| Lease liabilities (non-current) | 1.2—3.9% | 1.2+183%3.9% | 1.4+135%3.9% | 1.5+108%4.0% | 0.4−59.7%0.9% | 0.4−58.2%1.4% | 0.6−49.7%1.6% | 0.7−43.6%2.3% | 0.9−39.5%2.5% | 1.0—2.6% | 1.2—2.7% | 1.3—2.7% | 1.4—2.6% | |
| Total liabilities | 21—65.9% | 21−13.7%65.9% | 23−10.1%65.0% | 23+37.1%59.7% | 23+40.4%59.8% | 24+55.7%78.1% | 25+71.0%70.4% | 17+14.1%51.8% | 16+4.9%46.1% | 15—38.6% | 15—34.8% | 15—30.0% | 16—28.1% | |
| Retained earnings | −365—−1158% | −365—−1158% | −364—−1044% | −361—−943% | −359—−938% | −357—−1157% | −352—−983% | −339—−1055% | −335—−948% | −331—−824% | −323—−761% | −314—−645% | −309—−560% | |
| Total equity | 11—34.1% | 11+59.6%34.1% | 12+14.7%35.0% | 15−0.6%40.3% | 15−19.3%40.2% | 6.7−72.6%21.9% | 11−59.0%29.6% | 15−50.6%48.2% | 19−48.4%53.9% | 25—61.4% | 26—61.1% | 31—64.4% | 37—66.9% | |
| Total liabilities and equity | 32—100% | 32+2.3%100% | 35−2.7%100% | 38+18.9%100% | 38+8.2%100% | 31−23.1%100% | 36−15.5%100% | 32−34.0%100% | 35−36.0%100% | 40—100% | 42—100% | 49—100% | 55—100% | |
| Shares outstanding | 46—— | 46+345%— | 46+407%— | 46+1549%— | 36+1183%— | 10+294%— | 9.1−59.5%— | 2.8−83.8%— | 2.8+305%— | 2.6—— | 22—— | 17—— | 0.7r17—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−10.2%— | 0.0*−21.4%— | 0.0*−11.1%— | 0.0−7.7%8.0% | 0.0*0.0%— | 0.0*−15.2%— | 0.0*−28.9%— | 0.0−33.3%— | 0.0*−30.8%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 0.6−14.5%— | 0.1*−36.8%— | 0.1*−22.0%— | 0.1+35.0%45.0% | 0.2*−5.6%— | 0.2*+28.8%— | 0.2*+0.6%— | 0.1−37.5%— | 0.2*+11.7%— | 0.2*—— | 0.2*—— | 0.2—— | 0.1*—— | |
| Cash from operating activities | −11—— | −2.9*—— | −3.1*—— | −2.5—−819% | −2.9*—— | −4.3*—— | −4.7*—— | −4.8—— | −4.7*—— | −3.9*—— | −3.5*—— | −4.9—— | −6.5*—— | |
| Capital expenditure | — | −0.0*—— | — | — | 0*—— | −0.0*—— | — | — | 0*—— | 0*—— | — | — | −0.1*—— | |
| Cash from investing activities | — | −0.0*—— | — | — | 0*—— | −0.0*—— | — | — | 0*—— | 0*—— | — | — | −0.1*—— | |
| Debt issued | — | — | — | — | 0.0*—— | 0.0*—— | 0.1*—— | 1.4—— | — | — | — | — | — | |
| Debt repaid | — | — | — | — | — | — | — | −0.1—— | 0*—— | 0*—— | — | — | 0*—— | |
| Shares issued | — | — | — | — | — | 0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 12+26.3%— | −0.0*—— | −0.0*−100%— | 3.9+25.8%1289% | 8.5*+120729%— | −0.1*−104%— | 6.8*—— | 3.1—— | 0.0*—— | 3.7*—— | — | — | −1.5*—— | |
| Exchange-rate effect on cash | −0.1—— | 0.0*—— | 0.0*—— | −0.0−139%−12.0% | −0.0*—— | −0.1*−724%— | −0.0*−358%— | 0.1—— | −0.1*−262%— | 0.0*—— | 0.0*—— | −0.0—— | 0.1*—— | |
| Change in cash | 0.9—— | −2.9*—— | −3.1*−251%— | 1.4—458% | 5.5*—— | −4.6*—— | 2.1*—— | −1.6—— | −4.8*—— | −0.2*—— | −1.7*—— | −4.9—— | −8.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Theriva Biologics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Restructuring | 8-K | |
| Directors and officersShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $13 M | Private placement after listing | $10 to $50 million | 10 | options | SEC |
| Jul 2022 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Mar 2022 | $1 M | Private placement after listing | Under $2 million | 4 | equity | SEC |
| Sep 2017 | $12 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Oct 2012 | $11 M | No. 2 | $10 to $50 million | 22 | equity | SEC |
| Oct 2012 | $8 M | No. 1 | $2 to $10 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2018 | · | · | · | · | · | · | · | · | · | · | 8 | · | 8 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 8 people (33% of workforce) | Restructuring planSEC 8-K | “The reduction included 8 employees, which represented approximately 33% of its workforce as of November 29, 2018, the date affected employees were notified.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Theriva Biologics, Inc. compares in Biotechnology
- Market cap$10 M · higher than 10% of 726
- Price / book0.7× · lower than 87% of 534
- FCF yield-165.4% · higher than 3% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Theriva Biologics, Inc.🇺🇸 | $10 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 13, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 12, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Theriva Biologics, Inc.? Verify and update this profile — free
Show Theriva Biologics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.